No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Lucia Moiola et al.|Journal of Neurology|2018Cited by 54
Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomicsMaryam Omrani, Cinthia Farina, Rosaria Rita Chiarelli et al.|Brain Behavior and Immunity|2024Cited by 14
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumabAlessandra Sottini, Luisa Imberti, Virginia Quaresima et al.|Journal of Neuroimmunology|2023Cited by 1